KMT2D and Hyperglycemia: We detected a significant increase in MLL2 (Figure 2B) and WDR82 (Figure 2C) in HUVEC exposed to intermittent hyperglycemia, and such treatment did not alter the protein level expression of SET1A (Figure 2D), WDR5 (Figure 2D), SET1B (Figure 2E), and MLL1(NT) (Figure 2F).